Susceptibility of β-lactamase-producing enterococci to piperacillin with tazobactam

Pablo C. Okhuysen, Kavindra V. Singh, Barbara E. Murray

Research output: Contribution to journalArticlepeer-review

12 Scopus citations


The in vitro activity of piperacillin with and without tazobactam was evaluated against different inocula of 12 clinical isolates of β-lactamase-producing Enterococcus faecalis obtained from different geographic areas. Minimum inhibitory concentrations (MICs) of piperacillin alone at ∼103 colony-forming units (CFU)/spot ranged from 4 to 8 and from 4 to 8 μg/ml with piperacillin plus tazobactam. When ∼107 CFU/spot was used, MICs increased to a range of 128-1024 μg/ml piperacillin. This inoculum effect was reversed by the addition of tazobactam to piperacillin at a fixed concentration of 1 μg/ml or at a ratio of 8 : 1 (piperacillin relative to tazobactam) with an MIC90 of 16 2 μg/ml for the combination drug. In time-kill studies, four β-lactamase-producing (Bla+) cisolates were tested and demonstrated a decrease of ≥2 log10 with 8 or 16 μg/ml of piperacillin in combination with 4 μg of tazobactam, but not with piperacillin alone. A non-β-lactamase-producing isolate was equally inhibited by piperacillin alone and piperacillin plus tazobactam. Against a Bla+ isolate, the combination of piperacillin with tazobactam with streptomycin resulted in a synergistic effect relative to that of piperacillin with tazobactam; piperacillin plus streptomycin did not show synergism. Piperacillin in combination with tazobactam is active against enterococci that produce β-lactamase and, in combination with an appropriate aminoglycoside, could be a viable choice for therapy of enterococci that do not have high-level resistance to all aminoglycosides.

Original languageEnglish (US)
Pages (from-to)219-224
Number of pages6
JournalDiagnostic Microbiology and Infectious Disease
Issue number3
StatePublished - Oct 1993

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases


Dive into the research topics of 'Susceptibility of β-lactamase-producing enterococci to piperacillin with tazobactam'. Together they form a unique fingerprint.

Cite this